Immunocore Holdings plc reported $431M of revenue over the trailing twelve months, +21% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $431M (to Q2 2026). Net income: −$18M, trailing twelve months to Q2 2026. Free cash flow: −$41M, trailing twelve months to Q2 2026. Operating margin: −5.4%, trailing twelve months to Q2 2026.

IMCRImmunocore Holdings plc

Healthcare

$31.03-7.5% 1Y

$31.03

$27.7952 weeks$40.22

Latest close: below its 200-day averageOct 23, 2026what changed →

IMCR as reported

Immunocore Holdings plc reported $431M of revenue over the trailing twelve months, +21% on the year before. 9 reported series are charted on this page, each one as filed.

$431M

Revenue, trailing twelve months · to Q2 2026 · +21% against the twelve months before

Net income: −$18M
Net income · −11% year on year · trailing twelve months to Q2 2026
Free cash flow: −$41M
Free cash flow · −245% year on year · trailing twelve months to Q2 2026
Operating margin: −5.4%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IMCR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$431M	+21%	Q2 2026
Net income	−$18M	−11%	Q2 2026
EPS	−$0.37	−7.5%	Q2 2026
Gross margin	99%	n/a	Q2 2026
Operating margin	−5.4%	n/a	Q2 2026
Net margin	−4.4%	n/a	Q2 2026
ROE	−7.0%	n/a	Q2 2026
ROA	−2.5%	n/a	Q2 2026
Free cash flow	−$41M	−245%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.